Advertisement

Pathology & Oncology Research

, Volume 15, Issue 2, pp 225–229 | Cite as

Analysis of EGFR Gene Amplification, Protein Over-expression and Tyrosine Kinase Domain Mutation in Recurrent Glioblastoma

  • Judit Toth
  • Kristof Egervari
  • Almos Klekner
  • Laszlo Bognar
  • Janos Szanto
  • Zoltan Nemes
  • Zoltan Szollosi
Original Paper

Abstract

Gefitinib and erlotinib are both selective EGFR tyrosine kinase inhibitors (EGFR-TKIs) that have produced responses in a small subgroup of lung cancer patients. The strongest evidence for a role of EGFR in the biology of glioblastoma stems from clinical trials in which 15–20% of recurrent glioblastoma patients experienced significant tumour regression in response to these small-molecule EGFR kinase inhibitors. We examined the protein-kinase domain of the EGFR gene, EGFR protein expression and EGFR gene amplification in 20 cases of recurrent GBMs. EGFR protein over-expression was found in 65% of cases. EGFR protein over-expression was associated with EGFR gene amplification in 35% of cases, and with high polysomy in 15% of cases. No mutations were found in the TK domain of the EGFR gene. Our results confirm that mutations in the kinase domain are absent in recurrent GBM, and this might be a preponderant factor in the lack of major clinical responses of TKIs in GBM, recent studies have suggested that responsiveness to EGFR kinase inhibitors was strongly associated with coexpression of EGFRvIII and PTEN. Further prospective validation of EGFRvIII and PTEN as predictors of the clinical response to EGFR kinase inhibitors in recurrent GBM is strongly anticipated.

Keywords

Glioblastoma multiforme EGFR Kinase inhibitor treatment 

References

  1. 1.
    Bruner JM (1994) Neuropathology of malignant gliomas. Semin Oncol 21(2):126–138PubMedGoogle Scholar
  2. 2.
    Gilbert MR, Loghin M (2005) The treatment of malignant gliomas. Curr Treat Options Neurol 7(4):293–303PubMedCrossRefGoogle Scholar
  3. 3.
    Rich JN, Hans C, Jones B et al. (2005) Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res. 65(10): 4051–4058PubMedCrossRefGoogle Scholar
  4. 4.
    Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37(suppl 4):S9–S15PubMedCrossRefGoogle Scholar
  5. 5.
    Lynch TJ, Bell DW, SordellaR et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139PubMedCrossRefGoogle Scholar
  6. 6.
    Paez JG, Janne PA, Lee JC et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500PubMedCrossRefGoogle Scholar
  7. 7.
    Nathoo N, Goldlust S, Vogelbaum MA (2004) Epidermal growth factor receptor antagonists: novel therapy for the treatment of high-grade gliomas. Neurosurgery 54:1480–1488PubMedCrossRefGoogle Scholar
  8. 8.
    Barber TD, Vogelstein B, Kinzler KW et al. (2004) Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 351:2883–2883PubMedCrossRefGoogle Scholar
  9. 9.
    Kris MG, Natale RB, Herbst RS et al. (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149–2158PubMedCrossRefGoogle Scholar
  10. 10.
    Fukuoka M, Yano S, Giaccone G et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21:2237–2246PubMedCrossRefGoogle Scholar
  11. 11.
    Mellinghoff IK, Wang MY, Vivanco I et al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012–2024PubMedCrossRefGoogle Scholar
  12. 12.
    Rich JN, Reardon DA, Peery T et al. (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133–142PubMedCrossRefGoogle Scholar
  13. 13.
    Li B, Chang CM, Yuan M et al. (2003) Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res 63:7443–7450PubMedGoogle Scholar
  14. 14.
    Rich JN, Rasheed BK, Yan H (2004) EGFR mutations and sensitivity to gefitinib. N Engl J Med 351:1260–1261PubMedCrossRefGoogle Scholar
  15. 15.
    Aldape KD, Ballman K, Furth A et al. (2004) Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 63:700–707PubMedGoogle Scholar
  16. 16.
    De Pas T, Pelosi P, de Braud F et al. (2004) Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare. J Clin Oncol 22:4966–4970PubMedCrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2008

Authors and Affiliations

  • Judit Toth
    • 1
  • Kristof Egervari
    • 3
  • Almos Klekner
    • 2
    • 3
  • Laszlo Bognar
    • 2
    • 3
  • Janos Szanto
    • 1
    • 2
  • Zoltan Nemes
    • 3
  • Zoltan Szollosi
    • 3
  1. 1.Department of Oncology, Medical and Health Science CenterUniversity of DebrecenDebrecenHungary
  2. 2.Department of Neurosurgery, Medical and Health Science CenterUniversity of DebrecenDebrecenHungary
  3. 3.Department of Pathology, Medical and Health Science CenterUniversity of DebrecenDebrecenHungary

Personalised recommendations